Project description:Epstein-Barr virus (EBV) infection can engender severe B-cell lymphoproliferative diseases. The primary infection is often asymptomatic or causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder. Selective vulnerability to EBV has been reported in association with inherited mutations impairing T cell immunity to EBV. Herein, we report bi-allelic loss-of-function mutations variants in IL27RA that underlie an acute and severe primary EBV infection with a nevertheless favorable outcome requiring a minimal treatment. One mutant allele (rs201107107) was enriched in the Finnish population (MAF=0.0068) and carried a high risk of severe IM when homozygous. IL27RA codes for the a subunit of the receptor of IL-27. In the absence of IL27RA, phosphorylation of STAT1 and STAT3 in response to IL-27 is abolished in T cells. In in vitro studies, IL-27 exerts a synergistic effect on TCR-dependent T cell proliferation that is abolished in cells from the patients, leading to impaired expansion of potent anti-EBV effector cytotoxic CD8+ T cells. IL-27 is produced by EBV- infected B lymphocytes and an IL27RA-IL-27 autocrine loop is required for maintenance of EBV-transformed B cells. This potentially explains the eventual favorable outcome of the EBV-induced viral disease in IL27RA-deficient patients. Furthermore, we identified neutralizing anti-IL-27 autoantibodies in most individuals who developed sporadic IM and chronic EBV infection. Collectively, these results demonstrate the critical role of IL27RA-IL-27 axis in T cell immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected B cells.
Project description:RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells.
PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.
Project description:Epstein-Barr virus has been reported to regulate cellular microRNA expression in B cells. In the present study, we investigated the differential microRNAs modulated by Epstein-Barr virus in Naspharyngeal Carcinoma, using CapitalBio corporation's mammalian miRNA arrays. Three cellular models were used in this study: the human naspharyngeal carcinoma cell line TW03 as a blank control; TW03 transfected with Epstein-Barr virus encoded LMP1; TW03 transfected with Epstein-Barr virus encoded LMP2A
Project description:We report the application of cut&tag technology for high-throughput profiling of histone modifications Raji Epstein–Barr viral genome in reponse to bryostatin treatment. Dual- and tri-methylation of lysine 4 on histone H3 protein indicate genes that are actively expressed/regulated. Tri-methylation of lysine 27 on histone H3 protein marks genes that are negatively regulated or suppressed for expression.
Project description:Gene expression profile of AGS gastric carcinoma cell line infected in vitro with Epstein-Barr Virus. Some samples also contain are stably transfected with a dominant negative LMP1 construct.
Project description:The Epstein-Barr virus nuclear antigen 2 (EBNA2) initiates and maintains the proliferation of infected B cells. In search of additional cellular strategies, that control EBNA2 function, we have performed a label-free mass spectrometry-based quantification of cellular proteins in EBNA2 immuno-precipitates and found polo-like kinase 1 (PLK1) to be bound to EBNA2. EBNA2/PLK1 complex formation is strongly enforced by EBNA2 S379 phosphorylation catalyzed by the mitotic CYCLIN B/CDK1 complex.
Project description:Epstein-Barr virus has been reported to regulate cellular microRNA expression in B cells. In the present study, we investigated the differential microRNAs modulated by Epstein-Barr virus in Naspharyngeal Carcinoma, using CapitalBio corporation's mammalian miRNA arrays.
Project description:Gene expression profile of AGS gastric carcinoma cell line infected in vitro with Epstein-Barr Virus. Some samples also contain are stably transfected with a dominant negative LMP1 construct. 8 total samples. 4 biological replicates of EBV infected cells, 2 biological replicates with EBV infected cells with LMP1DN construct, and 2 biological replicates with EBV infected cells with control vector.